Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTP4A3 | O75365 | 7/20 | 0.58 |
| ▸ | PTP4A2 | Q12974 | 1/20 | 0.58 |
| ▸ | PTP4A1 | Q93096 | 1/20 | 0.58 |
| ▸ | ELANE | P08246 | 12/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22013197 | 0.78 | PTP4A3 (0.74) | PTP4A3PTP4A2PTP4A1 | |
| SCHEMBL22014148 | 0.76 | PTP4A3 (0.71) | PTP4A3PTP4A2PTP4A1 | |
| SCHEMBL21963442 | 0.75 | CDC7 (0.57) | ELANECA2 | |
| SCHEMBL22013811 | 0.75 | PTP4A3 (0.74) | PTP4A3PTP4A2PTP4A1 | |
| SCHEMBL22012119 | 0.75 | PTP4A3 (0.74) | PTP4A3PTP4A2PTP4A1 | |
| SCHEMBL18323037 | 0.75 | PTP4A3 (1.00) | PTP4A3PTP4A2PTP4A1 | |
| SCHEMBL22012120 | 0.74 | PTP4A3 (0.68) | PTP4A3PTP4A2PTP4A1 | |
| SCHEMBL22013809 | 0.74 | PTP4A3 (0.77) | PTP4A3PTP4A2PTP4A1 | |
| SCHEMBL24117878 | 0.72 | PTP4A3 (0.77) | PTP4A3PTP4A2PTP4A1 | |
| SCHEMBL22013199 | 0.72 | PTP4A3 (0.77) | PTP4A3PTP4A2PTP4A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12227515-B2 | In-flow photooxygenation of aminothienopyridinones generates novel PTP4A3 phosphatase inhibitors | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2025-02-18 | — | — | US | disclosed |
| US-12202839-B2 | In-flow photooxygenation of aminothienopyridinones generates PTP4A3 phosphatase inhibitors | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2025-01-21 | — | — | US | disclosed |
| US-20220017534-A1 | IN-FLOW PHOTOOXYGENATION OF AMINOTHIENOPYRIDINONES GENERATES NOVEL PTP4A3 PHOSPHATASE INHIBITORS | UNITED STATES GOVERNMENT | 2022-01-20 | — | — | US | disclosed |
| US-20220017534-A1 | IN-FLOW PHOTOOXYGENATION OF AMINOTHIENOPYRIDINONES GENERATES NOVEL PTP4A3 PHOSPHATASE INHIBITORS | UNITED STATES GOVERNMENT | 2022-01-20 | — | — | US | disclosed |
| US-20210395266-A1 | IN-FLOW PHOTOOXYGENATION OF AMINOTHIENOPYRIDINONES GENERATES NOVEL PTP4A3 PHOSPHATASE INHIBITORS | UNITED STATES GOVERNMENT | 2021-12-23 | — | — | US | disclosed |
| US-20210395266-A1 | IN-FLOW PHOTOOXYGENATION OF AMINOTHIENOPYRIDINONES GENERATES NOVEL PTP4A3 PHOSPHATASE INHIBITORS | UNITED STATES GOVERNMENT | 2021-12-23 | — | — | US | disclosed |
| EP-3880684-A1 | IN-FLOW PHOTOOXYGENATION OF AMINOTHIENOPYRIDINONES GENERATES NOVEL PTP4A3 PHOSPHATASE INHIBITORS | University of Virginia Patent Foundation (US) | 2021-09-22 | — | — | EP | disclosed |
| EP-3880200-A2 | IN-FLOW PHOTOOXYGENATION OF AMINOTHIENOPYRIDINONES GENERATES NOVEL PTP4A3 PHOSPHATASE INHIBITORS | University of Virginia Patent Foundation (US) | 2021-09-22 | — | — | EP | disclosed |
| WO-2020102243-A2 | IN-FLOW PHOTOOXYGENATION OF AMINOTHIENOPYRIDINONES GENERATES NOVEL PTP4A3 PHOSPHATASE INHIBITORS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2020-05-22 | — | — | WO | disclosed |
| WO-2020102245-A1 | IN-FLOW PHOTOOXYGENATION OF AMINOTHIENOPYRIDINONES GENERATES NOVEL PTP4A3 PHOSPHATASE INHIBITORS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017534-A1 | IN-FLOW PHOTOOXYGENATION OF AMINOTHIENOPYRIDINONES GENERATES NOVEL PTP4A3 PHOSPHATASE INHIBITORS | PTP4A3, PTPRC, PTPRF | PTP4A3 1/4885PTP4A2 5/4885PTP4A1 7/4885 |
| US-12202839-B2 | In-flow photooxygenation of aminothienopyridinones generates PTP4A3 phosphatase inhibitors | PTP4A3, PTPRO, PTPRC | PTP4A3 1/4885PTP4A2 5/4885PTP4A1 6/4885 |
| US-20210395266-A1 | IN-FLOW PHOTOOXYGENATION OF AMINOTHIENOPYRIDINONES GENERATES NOVEL PTP4A3 PHOSPHATASE INHIBITORS | PTP4A3, PTPRO, PTPRC | PTP4A3 1/4885PTP4A2 5/4885PTP4A1 6/4885 |
| US-12227515-B2 | In-flow photooxygenation of aminothienopyridinones generates novel PTP4A3 phosphatase inhibitors | PTP4A3, PTPRC, PTPRF | PTP4A3 1/4885PTP4A2 5/4885PTP4A1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.